Cargando…
Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
The pharmacological treatment of epilepsy is purely symptomatic. Despite many decades of intensive research, causal treatment of this common neurologic disorder is still unavailable. Nevertheless, it is expected that advances in modern neuroscience and molecular biology tools, as well as improved an...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917847/ https://www.ncbi.nlm.nih.gov/pubmed/36769250 http://dx.doi.org/10.3390/ijms24032928 |
_version_ | 1784886466434826240 |
---|---|
author | Łukasiuk, Katarzyna Lasoń, Władysław |
author_facet | Łukasiuk, Katarzyna Lasoń, Władysław |
author_sort | Łukasiuk, Katarzyna |
collection | PubMed |
description | The pharmacological treatment of epilepsy is purely symptomatic. Despite many decades of intensive research, causal treatment of this common neurologic disorder is still unavailable. Nevertheless, it is expected that advances in modern neuroscience and molecular biology tools, as well as improved animal models may accelerate designing antiepileptogenic and epilepsy-modifying drugs. Epileptogenesis triggers a vast array of genomic, epigenomic and transcriptomic changes, which ultimately lead to morphological and functional transformation of specific neuronal circuits resulting in the occurrence of spontaneous convulsive or nonconvulsive seizures. Recent decades unraveled molecular processes and biochemical signaling pathways involved in the proepileptic transformation of brain circuits including oxidative stress, apoptosis, neuroinflammatory and neurotrophic factors. The “omics” data derived from both human and animal epileptic tissues, as well as electrophysiological, imaging and neurochemical analysis identified a plethora of possible molecular targets for drugs, which could interfere with various stages of epileptogenetic cascade, including inflammatory processes and neuroplastic changes. In this narrative review, we briefly present contemporary views on the neurobiological background of epileptogenesis and discuss the advantages and disadvantages of some more promising molecular targets for antiepileptogenic pharmacotherapy. |
format | Online Article Text |
id | pubmed-9917847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99178472023-02-11 Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs Łukasiuk, Katarzyna Lasoń, Władysław Int J Mol Sci Review The pharmacological treatment of epilepsy is purely symptomatic. Despite many decades of intensive research, causal treatment of this common neurologic disorder is still unavailable. Nevertheless, it is expected that advances in modern neuroscience and molecular biology tools, as well as improved animal models may accelerate designing antiepileptogenic and epilepsy-modifying drugs. Epileptogenesis triggers a vast array of genomic, epigenomic and transcriptomic changes, which ultimately lead to morphological and functional transformation of specific neuronal circuits resulting in the occurrence of spontaneous convulsive or nonconvulsive seizures. Recent decades unraveled molecular processes and biochemical signaling pathways involved in the proepileptic transformation of brain circuits including oxidative stress, apoptosis, neuroinflammatory and neurotrophic factors. The “omics” data derived from both human and animal epileptic tissues, as well as electrophysiological, imaging and neurochemical analysis identified a plethora of possible molecular targets for drugs, which could interfere with various stages of epileptogenetic cascade, including inflammatory processes and neuroplastic changes. In this narrative review, we briefly present contemporary views on the neurobiological background of epileptogenesis and discuss the advantages and disadvantages of some more promising molecular targets for antiepileptogenic pharmacotherapy. MDPI 2023-02-02 /pmc/articles/PMC9917847/ /pubmed/36769250 http://dx.doi.org/10.3390/ijms24032928 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Łukasiuk, Katarzyna Lasoń, Władysław Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs |
title | Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs |
title_full | Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs |
title_fullStr | Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs |
title_full_unstemmed | Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs |
title_short | Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs |
title_sort | emerging molecular targets for anti-epileptogenic and epilepsy modifying drugs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917847/ https://www.ncbi.nlm.nih.gov/pubmed/36769250 http://dx.doi.org/10.3390/ijms24032928 |
work_keys_str_mv | AT łukasiukkatarzyna emergingmoleculartargetsforantiepileptogenicandepilepsymodifyingdrugs AT lasonwładysław emergingmoleculartargetsforantiepileptogenicandepilepsymodifyingdrugs |